Company intelligence / Profile preview

E-MO Biology Inc.

Arcadia, California, United Statesclinicalconnection.com ↗

Ownership: Private
Development stage: Phase 3

Overview

The company is applying with U.S. FDA for phase 4 clinical trial for a new intended use of market existing vaccine, Polio Vaccine, against SARS-CoV-2 in control and prevention of COVID-19. Their study indicates booster polio vaccine may reduce COVID-19 SARS-COV-2 infection and severity[3][7].

Therapeutic areas: Infectious Diseases
Modalities: Vaccines
Industry: Biotech

Drug pipeline

1 asset

inactivated poliovirus vaccine

Phase 4

Indications: COVID-19

Partnerships

HWGB Biotech Sdn BhdFuse Biotech Inc.

Beyond the preview

Go deeper on E-MO Biology Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E-MO Biology Inc..

Explore the full profile